Abstract:Introduction and objectives Hepatocellular carcinoma (HCC) is the most common liver neoplasm in the world. Inflammatory, oxidative and fibrogenic processes are key in tumor development and propagation. Pirfenidone (PFD) has been shown to have hepatoprotective, anti-fibrogenic and immunomodulatory properties during hepatocarcinogenesis. However, its effect on established HCC is unknown. Our aim is to evaluate the effect of PFD administration on the tumor and inflammatory microenvironment in an experimental hepatocellular carcinoma model. Materials and Patients Fischer-344 rats (n=18) protocolized into three groups: CTL: control, HCC: damage group, (induced by diethylnitrosamine (DEN) 50 mg/kg and 2-acetaminofluorene (2AAF) 25mg/kg/weekly for 16 weeks), HCC/PFD: damage group + administration of PFD 300 mg/kg/daily. Subsequently, immunoassays and histological analyzes were performed to assess inflammatory patterns, fibrosis, and malignancy. All animals received human care, and all the experiments were performed according to the Guide for the Care and Use of Laboratory Animals, under the approval of the Research, Ethics, and Biosafety committees of the CUCS whit approval number CI-03020. Results In the HCC/PFD group, the observed nodules were smaller in number, size, and protrusion compared to the HCC group. Additionally, there was a decrease in fibrosis development, extracellular matrix synthesis, as well as collagen and α-SMA expression. The loss of hepatic architecture was restored, and there was a decrease in the percentage of transformed hepatocytes positive for Glypican-3 expression, in contrast to the HCC group. Furthermore, there was a restoration of p53 expression. Moreover, the local secretome showed a decrease in IL-10 and an increase in IL-6 and IL-1β compared to the HCC group. Finally, the expression and localization of CD45 and CD161 were observed to be increased within the tumor niches compared to the HCC group. Conclusions Treatment with PFD slows the development of both macroscopic and microscopic patterns of malignancy and fibrosis, decreases the activation of hepatic stellate cells, the local inflammatory secretome, and modulates the components of the tumor microenvironment, thus improving the conditions and progression of the neoplasia. Therefore, pirfenidone could mean an improvement in the quality of life and an increase in the survival of patients with HCC in advanced stages.

Pirfenidone attenuates nonalcoholic fatty liver disease through activation of the nuclear factor erythroid 2‐related factor 2 (Nrf2) signaling pathway

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Pirfenidone Prevents and Reverses Hepatic Insulin Resistance and Steatohepatitis by Polarizing M2 Macrophages.

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel

Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways

Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice

Puerarin protects against high‐fat high‐sucrose diet‐induced non‐alcoholic fatty liver disease by modulating PARP‐1/PI3K/AKT signaling pathway and facilitating mitochondrial homeostasis

Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice

P-3 PIRFENIDONE PREVENTS OBESITY-ASSOCIATED NONALCOHOLIC STEATOHEPATITIS AND CARDIAC FIBROSIS THROUGH HORMONAL REPROGRAMMING

Hepatoprotective efficacy and interventional mechanism of the panaxadiol saponin component in high-fat diet-induced NAFLD mice

Puerarin ameliorates non-alcoholic fatty liver disease by inhibiting lipid metabolism through FMO5

Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro.

Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model

Puerarin Ameliorates Nonalcoholic Fatty Liver in Rats by Regulating Hepatic Lipid Accumulation, Oxidative Stress, and Inflammation

Pirfenidone effectively reverses experimental liver fibrosis

Apigenin, a Modulator of PPARγ, Attenuates HFD-induced NAFLD by Regulating Hepatocyte Lipid Metabolism and Oxidative Stress Via Nrf2 Activation

Treatment With Ppar Delta Agonist Alleviates Non-Alcoholic Fatty Liver Disease By Modulating Glucose And Fatty Acid Metabolic Enzymes In A Rat Model

Targeting antioxidant factor Nrf2 by raffinose ameliorates lipid dysmetabolism-induced pyroptosis, inflammation and fibrosis in NAFLD